Quest Diagnostics Incorporated (DGX)
Automate Your Wheel Strategy on DGX
With Tiblio's Option Bot, you can configure your own wheel strategy including DGX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol DGX
- Rev/Share 93.9464
- Book/Share 65.5893
- PB 2.5941
- Debt/Equity 0.8832
- CurrentRatio 1.086
- ROIC 0.0776
- MktCap 18720288430.0
- FreeCF/Share 10.9286
- PFCF 15.2944
- PE 19.7576
- Debt/Assets 0.3998
- DivYield 0.0185
- ROE 0.1368
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 5
- P/B Score 3
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | DGX | Redburn Atlantic | -- | Buy | -- | $195 | April 2, 2025 |
| Downgrade | DGX | Citigroup | Buy | Neutral | -- | $185 | March 4, 2025 |
| Upgrade | DGX | Leerink Partners | Market Perform | Outperform | $169 | $174 | Jan. 6, 2025 |
| Upgrade | DGX | Morgan Stanley | Equal Weight | Overweight | $145 | $172 | Dec. 17, 2024 |
| Resumed | DGX | Jefferies | -- | Buy | $175 | $185 | Dec. 10, 2024 |
| Upgrade | DGX | Robert W. Baird | Neutral | Outperform | $157 | $182 | Oct. 23, 2024 |
| Resumed | DGX | Evercore ISI | -- | In-line | -- | $165 | Aug. 28, 2024 |
News
Fresenius Medical Care Announces Divestment of Select Laboratory Assets to Quest Diagnostics
Published: February 24, 2025 by: PRNewsWire
Sentiment: Neutral
Quest to provide comprehensive dialysis-related laboratory and water testing services to Fresenius Medical Care owned and affiliated clinics in the United States BAD HOMBURG, Germany and SECAUCUS, N.J. , Feb. 24, 2025 /PRNewswire/ -- Fresenius Medical Care (XETRA: FME; NYSE: FMS), the world's leading provider of products and services for individuals with renal disease, and Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that, under terms of a definitive acquisition agreement, Quest will acquire select assets of FME's wholly owned Spectra Laboratories, a leading provider of renal-specific laboratory testing services in the U.S. In addition, …
Read More
Quest Diagnostics to Host Investor Day on March 19, 2025
Published: February 13, 2025 by: PRNewsWire
Sentiment: Neutral
SECAUCUS, N.J. , Feb. 13, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, will host an Investor Day for institutional investors and financial analysts in New York City on Thursday, March 19, 2025 at the New York Stock Exchange.
Read More
Why Quest Diagnostics (DGX) is a Top Momentum Stock for the Long-Term
Published: February 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
About Quest Diagnostics Incorporated (DGX)
- IPO Date 1996-12-17
- Website https://www.questdiagnostics.com
- Industry Medical - Diagnostics & Research
- CEO James E. Davis
- Employees 55000